StockData
Mereo BioPharma Group plc logo

Mereo BioPharma Group plc (MREO) stock

MREONasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 9, 2026Score 1/30
$0.29+0.01 (+5.39%)

Close on Nov 18, 2026Market cap $46.20MP/E –Yield –

Mereo BioPharma operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

Mereo BioPharma's operating cash flow for the twelve months ending Sep 30, 2026 was -$22.09M. For fiscal 2025 it was -$30.97M.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$30.97M–
FY2024Dec 31, 2024-$32.83M–
FY2023Dec 31, 2023-$21.13M–
FY2022Dec 31, 2022-$48.82M–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026-$4.05M–
Q2 FY2026Jun 30, 2026-$6.04M–
Q1 FY2026Mar 31, 2026-$4.31M–
Q4 FY2025Dec 31, 2025-$7.68M–
Q3 FY2025Sep 30, 2025-$7.31M–
Q2 FY2025Jun 30, 2025-$7.65M–
Q1 FY2025Mar 31, 2025-$8.33M–
Q4 FY2024Dec 31, 2024-$9.42M–
Q3 FY2024Sep 30, 2024-$7.52M-382.8%
Q2 FY2024Jun 30, 2024-$7.90M–
Q1 FY2024Mar 31, 2024-$7.99M–
Q4 FY2023Dec 31, 2023-$6.79M–
Q3 FY2023Sep 30, 2023$2.66M–
Q2 FY2023Jun 30, 2023-$7.75M–
Q1 FY2023Mar 31, 2023-$9.25M–

More Mereo BioPharma figures

See a number that looks wrong?